Lin, Ming-HongMing-HongLinLee, Kin-MuKin-MuLeeCHE-YUAN HSUPeng, Shih-YiShih-YiPengLin, Ching-NanChing-NanLinChen, Chin-ChuChin-ChuChenFan, Chia-KwungChia-KwungFanCheng, Po-ChingPo-ChingCheng2025-09-082025-09-082019-08https://scholars.lib.ntu.edu.tw/handle/123456789/731893In this study, we examined the ability of A. blazei Murill polysaccharides (AB-PS) to activate the immune system in vivo and the protective activity exhibited against parasitic S. mansoni in the murine model. AB-PS treatment significantly reduced the worm and egg burden in infected BALB/c and C57BL/6 mice with dose- and time-dependent manners. Additionally, a dose- and time-dependent expression of IL-2, INF-γ, and TNF-α cytokines was also observed in both strains of mice treatments. Using T1/T2 doubly transgenic mice, we demonstrated that AB-PS-treated mice splenocytes initiated early differentiation of Th1 and NK1 cells, which was consistent with the reduction course of Schistosoma infection. Although AB-PS treatment enhanced the Th1 response, it did not suppress Th2 cell activity in treated mice. Histopathological data of the livers showed AB-PS treatment significantly attenuated the liver fibrosis induced by S. mansoni eggs. AB-PS augmented type-1 responses by inducing Th1 and NK1 cell differentiation to effectively decrease the infection rate of S. mansoni. Furthermore, AB-PS treatment may not only inhibit the schistosome infection, but also improving the pathological effects of granulomas formation. This study provides evidence for a novel therapeutic potential, by which A. blazei Murill may be used to treat or prevent schistosome infection.enAgaricus blazei Murill polysaccharidesImmunomodulationNK cellSchistosoma mansoniT1/T2 doubly transgenic mice[SDGs]SDG3journal article10.1016/j.intimp.2019.05.04531173972